Impact of a clinical guidelines program for breast and colon cancer in a French cancer center

JAMA

Volumn 278, Issue 19, 1997, Pages 1591-1595

  Ray Coquard, Isabelle ^a   Philip, Thierry ^a,b   Lehmann, Michel ^b   Fervers, Béatrice ^b   Farsi, Fadila ^a   Chauvin, Franck ^a  

^a CENTRE LÉON BÉRARD   (France)

^b FNCLCC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST CANCER; COLON CANCER; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0030726797     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.19.1591     Document Type: Article

References (45)

1. Field MJ, Lohr KN, eds. Clinical Practice Guidelines. Washington, DC: Institute of Medicine, National Academy Press; 1990:38.
2. Browman GP, Levine A, Mohide EA, et al. The practice guidelines development cycle. J Clin Oncol. 1995;13:502-512.
3. Hayward RS, Laupacis A. Initiating, conducting and maintaining guidelines development programs. Can Med Assoc J. 1993;148:507-512.
4. Grimshaw JM, Russel TI. Effect of clinical guidelines on medical practice. Lancet. 1993;342:1317-1322.
5. Woolf SH. Practice guidelines: a new reality in medicine, III: impact of patient care. Arch Intern Med. 1993;153:2646-2655.
6. Grilli R, Lomas J. Evaluating the message: the relationship between compliance rate and the subject of a practice guideline. Med Care. 1994;32:202-213.
7. Eddy DM. The individual vs society: is there a conflict? JAMA. 1991;265:1446-1450.
8. Eddy DM. Guidelines for policy statements: the explicit approach. JAMA. 1990;263:2239-2243.
9. Farrow DC, Hunt WC, Samet JM. Geographic variation in the treatment of localized breast cancer. N Engl J Med. 1992;326:1097-1101.
10. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74:979-983.
11. Woolf SH. Practice guidelines: a new reality in medicine, II: methods of developing guidelines. Arch Intern Med. 1992;152:946-952.
12. Margolis CZ. Uses of clinical algorithms. JAMA. 1983;249:627-632.
13. Donabedian A. The Criteria and Standards of Quality, II. Ann Arbor, Mich: Health Administration Press; 1982.
14. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989;95:2S-4S.
15. Union Internationale Contre le Cancer. U.I.C.C, TNM: Classification des Tumeurs Malignes. 4th ed. Paris, France: Springer-Verlag; 1988:99-105.
16. Asler VB, Coller FA. The prognostic significance of direct extension of cancer of the colon and rectum. Ann Surg. 1954;139:846-852.
17. French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol. 1988;6:679-688.
18. Coombes RC, Bliss JM, Morvan F, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer. J Clin Oncol. 1996;14:35-45.
19. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet. 1992;339:1-15.
20. Shaake Koning C, VanderLinden EH, Hart G, Engelsman E. Adjuvant chemo- and hormonal therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 1985;11:1759-1763.
21. Scholl SM, Fourquet A, Asselain B, et al. Neo-adjuvant versus adjuvant chemotherapy in pre-menopausal patients with tumors considered too large for breast conserving surgery. Eur J Cancer. 1994;30A:645-652.
22. Rutqvist LE, Pettersson D, Johansson H. Adjuvant radiation therapy versus surgery alone in operable breast cancer. Radiother Oncol. 1993;6:104-110.
23. Margolese RG, Foster RS Jr. Tamoxifen as an alternative to surgical resection for selected geriatric patients with primary breast cancer. Arch Surg. 1989;124:548-550.
24. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993; 11:1879-1887.
25. Rougier P, Paillot B, Laplanche A, et al. End results of a multicentric randomized trial comparing 5 FU in continuous systemic infusion to bolus administration in measurable metastatic colorectal cancer. Proc Am Soc Clin Oncol. 1992;111:63 Abstract.
26. Budd GT, Fleming TR, Budkowski RM, et al. 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. J Clin Oncol. 1987;5:272-277.
27. Moertel CG, Fleming TR, Macdonald JS, et al. Levamizol and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322: 352-358.
28. Zaniboni A, Erlichman C, Seitz JF, et al. FUFA increases disease-free survival (DFS) in resected B2C colon cancer (CC). Proc Am Soc Clin Oncol. 1993;12:191. Abstract.
29. Rougier P, Laplanche A, Huguier CM, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma. J Clin Oncol. 1992;10:1112-1118.
30. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depish D. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993;306:752-765.
31. Jager J, Merkle E, Lang N. Erlangen tumor marker study on breast cancer. J Tumor Marker Oncol. 1991;6:56-59.
32. Calle R, Gongora R, Vilcoq JR, Desprez P, Schilienger P. Cancers du sein. Bull Cancer. 1980;67:313-317.
33. Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993;328:1587-1591.
34. Wazer DE, Erban JK, Robert NJ, et al. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection. Cancer. 1994;74:878-883.
35. Lagios MD, Whesthal PR, Margolin FR, Rose MR. Duct carcinoma in-situ. Cancer. 1982;50:1309-1314.
36. Sunshine JA, Moseley HS, Fletcher WS, Krippaehne WW. Breast carcinoma in-situ. Am J Surg. 1985;150:44-51.
37. Alle PE, Tepper JE, Gunderson LL, Munzenrider JE. Postoperative radiation therapy for incompletely resected carcinoma. Int J Radiat Oncol Biol Phys. 1989;17:1171-1176.
38. Sherman DM, Welchselbaum R, Order SE, Cloud L, Trey C, Piro AJ. Palliation of hepatic metastases. Cancer. 1978;41:2013-2017.
39. Livraghi T, Claudio V, Lazzaroni S. Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology. 1990;179:709-712.
40. Jakesz R, Stege G. Primary (preoperative, neo-adjuvant) chemotherapy of colon cancer: a therapeutic alternative? Chirurg. 1994;65:497-502.
41. Coburn MC, Pricolo VE, Soderberg CH. Factors affecting prognosis and management of carcinoma of the colon and rectum in patients more than eighty years of age. J Am Coll Surg. 1994;179:65-69.
42. Hugues K, Foster J. The role of adjuvant chemotherapy following curative hepatic resection of colo-rectal metastases. Proc Am Soc Clin Oncol. 1991;10:145. Abstract.
43. Bekrada M, Culine S, Mathieu-Boue A, Mahjoubi M. Etude de phase II du CPT 11 en première ligne dans les cancers colorectaux métastatiques: résultats préliminaires. Bull Cancer. 1994;6:562-563.
44. Federation Nationale des Centres de Lutte Contre le Cancer. Standards, Options, Recommandations pour la Prise en Charge des Patients Atteints de Cancer du Côlon. Paris, France: Arnette Blackwell SA; 1995:110-126.
45. Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med. 1993;329:1271-1274.